Document is current

Article History

First Online: 10 December 2024

Competing interests

: J.H.C. receives research support from the Society for Immunotherapy of Cancer AstraZeneca fellowship and a sponsored research agreement with Calico labs and previously with Novartis. J.H.C. consults for Merck and has also received a speaking honorarium from the Society for Interventional Oncology and has non-paid technology materials transfer agreements with NanoString and Vizgen. J.F.G. has served as a compensated consultant for Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol Myers Squibb, Genentech, Gilead Sciences, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly/Loxo, Merck, Moderna Therapeutics and Takeda; has received honorarium from Novartis, Merck, Novartis, Pfizer and Takeda; has received institutional research funding from Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, NextPoint Therapeutics and Palleon Pharmaceuticals; has received research support from Novartis, Genentech and Takeda and has equity in AI Proteins; and has an immediate family member who has equity in and is employed by Ironwood Pharmaceuticals.